R.E.M.S. technology reaches the oceanic continent.
We are proud to announce the achievement of sales authorization for the Echolight products issued by the Australia Government Department of Health. So Australia is also opening its doors to R.E.M.S. (Radiofrequency Echographic Multi Spectrometry) bringing the presence of Echolight to over 40 countries around the world.
R.E.M.S. is the innovative technology running the operation of the EchoS densitometer which performs in a few minutes an ultrasound scan of the bone without radiation, delivers the report in real time being able to check the bone health status and then reduce the risk of fragility fracture, as a consequence of osteoporosis.
Being now used in hundreds of hospitals and clinical centers around the world, the device is also available in Australia thanks to the collaboration with an important local partner with the purpose of introducing a new concept of bone health, based on prevention, early diagnosis and bone structure monitoring.
For more info, please visit www.echolight.com.au
REMS & Diabete
The Advantages of REMS Technology in Type 2 Diabetes Mellitus The study “Utility of REMS-Derived Fragility Score and Trabecular Bone Score in Evaluating Bone Health in Type 2 Diabetes Mellitus” recently published by Al Refaie and colleagues in Diagnostics Journal...
REMS Performance
The very recent study titled “Proposed practice parameters for the performance of radiofrequency Echographic multispectrometry (REMS) evaluations” and published on the Bone Joint Open by international key Opinion Leaders from USA and UK showed that REMS are becoming a...
Position Paper by ESCEO
“Radiofrequency echographic multi spectrometry (REMS) in the diagnosis and management of osteoporosis: state of the art.” ESCEO WORKING GROUPNicholas R Fuggle, Jean-Yves Reginster · Nasser Al-Daghri · Olivier Bruyere · Nansa Burlet · Claudia Campusano6 · Cyrus Cooper...